PRESENTATION OF Q2-2023 REPORT

Presenters from Ascelia Pharma:

CEO Magnus Corfitzen | Deputy CEO & CCO Julie Waras Brogren
CSO Andreas Norlin | CFO Déspina Georgiadou Hedin

ASCELIA PHARMA

Share ticker: ACE
Nasdaq Stockholm

WEBCAST:
18 Aug 2023, 10:00AM CET

Link webcast:

If you wish to participate via webcast, please use the link below.

https://ir.financialhearings.com/ascelia-pharma-q2-2023

If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference.

https://conference.financialhearings.com/teleconference/?id=5001498

ADVANCING ORPHAN ONCOLOGY

FORWARD LOOKING STATEMENTS

This presentation, which includes all information and data on the following slides, any oral statements made when presenting these slides, and any other material distributed or statements made at, or in connection with, such presentation (the "Presentation"), relates to Ascelia Pharma AB (publ) (hereinafter, together with its subsidiaries, the "Company") is furnished to you solely for your information and may not be reproduced or redistributed, in whole or in part, to any other person without the prior written consent of the Company. You should not rely upon it or use it to form the definitive basis for any decision, contract, commitment or action whatsoever, with respect to any transaction or otherwise.

The information included in this Presentation may contain certain forward-looking statements relating to the business, financial performance and results of the Company and/or the industry in which it operates. Forward-looking statements concern future circumstances and results and other statements that are not historical facts, sometimes identified by the words "believes", "expects", "predicts", "intends", "projects", "plans", "estimates", "aims", "foresees", "anticipates", "targets", and similar expressions. The forward-looking statements contained in this Presentation, including assumptions, opinions and views of the Company or cited from third party sources are solely opinions and forecasts which are subject to risks, uncertainties and other factors that may cause actual events to differ materially from any anticipated development. Neither the Company nor any of its affiliates, directors, employees or advisors provides any assurance that the assumptions underlying such forward-looking statements are free from errors nor do any of them accept any responsibility for the future accuracy of the opinions expressed in this Presentation or the actual occurrence of the forecasted developments. This Presentation speaks as of the applicable reporting date, and there may have been changes in matters which affect the Company subsequent to the date of this Presentation. Neither the issue nor delivery of this Presentation shall under any circumstance create any implication that the information contained herein is correct as of any time subsequent to the date hereof or that the affairs of the Company have not since changed, and the Company does not intend, and does not assume any obligation, to update or correct any information included in this Presentation.

Each person should make their own independent assessment of the merits of the Company and should consult their own professional advisors. By receiving this Presentation, you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own opinion of the potential future performance of the Company's business.

ASCELIA PHARMA – HIGHLIGHTS

ADVANCING ORPHAN ONCOLOGY

- Identify, develop and commercialize novel drugs that address unmet needs in rare cancers
- Two drugs in advanced clinical development
  - **ORVIGLANCE** – Phase 3 patient enrollment completed; FDA Orphan Drug Designation
  - **ONCORAL** – Ready for Phase 2

BUILDING GLOBAL CAPABILITIES

- Based in Malmö (Sweden), US affiliate in New Jersey (US)
- Listed on NASDAQ Stockholm (Ticker: ACE)

ASCELIA PHARMA

RECENT KEY EVENTS

Key events in Q2-2023

- Hepatic impairment study accepted for presentation at major radiology and liver conferences
- Ascelia Pharma presented Orviglance hepatic impairment data and hosted a Q&A with liver imaging experts at the 2023 ESGAR annual meeting

Key events after Q2-2023

- Re-evaluation required after intra-reader inconsistency in scoring of images from phase 3 study SPARKLE
- Clarification that images were not read and scored properly

RE-EVALUATION REQUIRED TO REACH RESULTS

High Intra-Reader Variability

- As per FDA guidance, a pre-defined number of patients were evaluated twice, which showed a high level of variability in the evaluation of images by some readers
- A re-evaluation of all images by a new group of independent radiology readers is required

Plan Ahead

- All activities and resources will now be focused on the re-evaluation
- Ascelia sees no need for enrollment of more patients or an additional clinical study
- Cost-saving initiatives are taken
- A timeline and financial implications for the re-evaluation will be presented by mid-September

ASCELIA PHARMA

PORTFOLIO

ORVIGLANCE

Liver diagnostic drug in ongoing Phase 3

ONCORAL

Daily oral chemotherapy ready for Phase 2

ASCELIA PHARMA

ORVIGLANCE PHASE 3, SPARKLE, SUCCESSFUL IF 2 OF 3 READERS REACH SIGNIFICANCE

SPARKLE CLINICAL STUDY

	Number of patients	Liver lesion types*	Primary endpoint	Image evaluation by readers	Superior to unenhanced	Statistical significance
SPARKLE – Phase 3 Study	85	Known or Suspected Lesion (Metastases, primary tumors, benign lesions)	Co-primary: Border Delineation; Lesion Contrast	Reader 1	?	P<x
				Reader 2	?	P<x
				Reader 3	?	P<x

* Apart from the difference in population heterogeneity, other differences between P004A Re-read and SPARKLE includes e.g., dose and MR hardware/software technology

ASCELIA PHARMA

UNRELIABLE MEASUREMENTS - EFFICACY NOT EVALUABLE

- Two readers with high level of intra-reader variability
- High intra-reader variability means the scorings are unreliable
- Unreliable scoring cannot be used to evaluate the effect
- All clinical data has been collected and no further patient enrollment is needed

SPARKLE CLINICAL STUDY

Unenhanced and Orviglance enhanced images from 85 patients

Intra-Reader Variability Assessment



ASCELIA PHARMA

ORVIGLANCE – FILLING AN UNMET NEED IN LIVER MRI

Patient Landscape

Liver metastases critical in cancer care

Liver metastases are common in many cancer types and often the cause of mortality [1-3]

- Colorectal cancer, metastatic breast cancer, gastric cancer

Treatments

Contrast enhanced MRI is the gold standard

Contrast enhanced MRI

- Detection and visualization
- Surgery & drug treatment plan
- Post-treatment surveillance

Unmet Need

A role for ORVIGLANCE in patients with kidney impairment

Patients with healthy kidneys

- Receive MRI with gadolinium-based contrast agent (GBCA)

Patients with severe kidney impairment

- Black Box warning for gadolinium contrast agents
- Risk of severe side effects, incl. Nephrogenic Systemic Fibrosis

ORVIGLANCE

Aims to be the imaging option without gadolinium-related safety risks patients with poor kidney function

- Manganese based
- Liver specific

1) Riihimäki, M. *et al.* Patterns of metastasis in colon and rectal cancer. *Sci. Rep.* 6, 29765; doi: 10.1038/srep29765 (2016); Journal of Pathology, 2014, 232:23-31
2) Guy diSibio and Samuel W. French (*2008*) Metastatic Patterns of Cancers: Results From a Large Autopsy Study. Archives of Pathology & Laboratory Medicine: June 2008, Vol. 132, No. 6, pp. 931-939
3) Rahbari et al. Metastatic Spread Emerging From Liver Metastases of Colorectal Cancer: Does the Seed Leave the Soil Again? Annals of Surgery: February 2016 - Volume 263 - Issue 2 - p 345–352

ASCELIA PHARMA

UNCHANGED CONFIDENCE IN ORVIGLANCE

- A well-defined unmet need for liver imaging in cancer patients with poor kidney function
- A global addressable market opportunity of USD 800 million
- Consistent positive efficacy and safety in eight completed Phase 1 and 2 studies
- Patient recruitment and MR image collection for SPARKLE Phase 3 study completed
  - Common adverse events were in line with previous studies
  - Efficacy conclusions from pending re-evaluation



ATTRACTIVE ADDRESSABLE MARKET



Global addressable market of USD 800 million

Well defined unmet need for liver imaging in cancer patients with severe kidney impairment

Attractive pricing and access opportunity based on recognized value proposition[1]

Underlying growth driven by prevalence and cancer survival as well as access and quality of care in rest of world markets[2]

Sources:
Ascelia Pharma market research with Decision Resources Group, 2020.
Ascelia Pharma market access research and analyses with Revenue Reimbursement Solutions and Charles River Associates (2020), Triangle (2022) and Trinity (2022), incl. 75 stakeholder and expoert interactions
1) Final pricing strategy is subject to Phase 3 data, payer evidence, negotiations, discounts and access strategy
2) In rest of world markets addressable market patient population incorporates restricted access to care, with market-based assumptions ranging from 10% upwards

ATTRACTIVE US OPPORTUNITY

Abdominal imaging procedures in cancer patients with severe kidney impairment (CKD 4/5/AKI)
based on epidemiology and real-world data[1]

~100,000 procedures annually

Pricing range benchmarks
based on innovative diagnostics, payer and expert input and price testing[2, 3]

$3,000-4,500

Volume growth driven by demographics as well as prevalence and long-term care in cancers and kidney disease

4-5% vol. annually

Sources:
1) Ascelia Pharma market research with Decision Resources Group, 2020. Literature on prevalence and epidemiology of kidney disease, cancer and liver metastases.
2) Ascelia Pharma market access research and analyses with Revenue Reimbursement Solutions and Charles River Associates (2020), Triangle (2022) and Trinity (2022)
3) Final pricing strategy is subject to Phase 3 data, payer evidence, negotiations, discounts and access strategy

ASCELIA PHARMA

UNMET NEED RECOGNIZED

NSF* risk
with warnings for target population

+90%

of HCPs are concerned by issues relating to GBCAs (including NSF)

+16%

of providers have experienced GBCA-induced NSF

*nephrogenic systemic fibrosis

Source: Independent research by Two Labs Pharma Services for Ascelia Pharma in the USA conducted in Q4 2021/Q1 2022 included 16 in depth interviews and a survey of 254 healthcare professionals (HCPs), including 154 radiologists, 50 nephrologists and 50 oncologists. Participants in the study were asked about their choices of imaging and contrast agents in patients with cancer

ASCELIA PHARMA

MOMENTUM FOR AN ALTERNATIVE TO GADOLINIUM

Deposition in brain & organs

concerns around safety for all patients

New safety category recommended for Symptoms Associated with Gadolinium exposure (SAGE), by Am. College of Rad. (2022)

Multiple-GBCA effect on body movement and mental skills study requested by the FDA (ODYSSEY, 2020)


frontiers in Molecular Neuroscience

published: 20 S
doi: 10.3389/fnm

healthcare-in-europe.com

Gadolinium Deposition in Brain: Current Scientific Evidence and Future Perspectives

Bang J. Guo[1], Zhen L. Yang[2] and Long J. Zhang[1,2]*

[1] Department of Medical Imaging, Jinling Hospital, Nanjing Clinical School, Southern Medical University, Nanji
[2] Department of Medical Imaging, Jinling Hospital, Medical School of Nanjing University, Nanjing, China

Water contamination

scrutiny of environmental impact

Gadolinium is excreted in urine. Hard to remove in our sewage systems, it is discharged into our environment and drinking water

> "The increasing use of gadolinium-based contrast agents (GBCAs) for MRI is leading to widespread contamination of freshwater and drinking water systems"[1]

Future with less/no gadolinium

focus of leading gadolinium manufactures

Low dose full-body gadolinium contrast agents

- FDA approved in priority review (gadopiclenol, Guerbet/Bracco 2022)
- Initiation of Phase 3 (gadoquatrane, Bayer 2023)

Completion of Phase 1 patient enrollment in full-body IV manganese-based contrast agent (GE HealthCare 2023)

1) Brünjes R. et al. Anthropogenic gadolinium in freshwater and drinking water systems, Water Research, Volume 182, 2020..
Other sources include:
Macke et al. Fast and automated monitoring of gadolinium-based contrast agents in surface waters, Water Research, Volume 207, 2021.
Oluwasola et al, Gadolinium based contrast agents (GBCAs): Uniqueness, aquatic toxicity concerns, and prospective remediation. Journal of Contaminant Hydrology, Volume 250, 2022.
M. Nicholl. Seeking alternatives to gadolinium-based contrast agents. Healthcareineurope.com. July 22022
Bang G. Gadolinium Deposition in Brain: Current Scientific Evidence and Future Perspectives. Mol. Neurosci., 20 September 2018.

ASCELIA PHARMA

PORTFOLIO

ORVIGLANCE

Liver contrast agent in ongoing Phase 3

ONCORAL

Daily oral chemotherapy ready for Phase 2

ASCELIA PHARMA

IMPROVING IRINOTECAN **EFFICACY** and **TOLERABILITY**

Irinotecan intravenous bolus dosing

ONCORAL – irinotecan oral daily dosing



ONCORAL PHASE 2 IN GASTRIC CANCER

STRONG RATIONALE FOR GASTRIC CANCER

- High unmet need and clinically demonstrated
- Potential for synergistic effect between Lonsurf and irinotecan

Efficacy study in an animal model of gastric cancer[1]
(Relative Tumor Volume, RTV)



Control arm

IV irinotecan (CPT-11)
Lonsurf (TAS-102)

Lonsurf + IV irinotecan

LONSURF AND IRINOTECAN COMBINATION

RANDOMIZED CONTROLLED PHASE 2 STUDY

- ~100 patients with metastatic gastric cancer
- Study arms: Oncoral + Lonsurf vs. Lonsurf
- Endpoints: Progression Free Survival (Primary), Response Rate, PK, Safety (Secondary) and Overall Survival (follow-up)
- IND approved in the US
- To focus all resources on Orviglance, patient enrollment is not initiated until it can be done effectively

Clinical collaboration with

TAIHO ONCOLOGY

LONSURF is approved for treatment of metastatic gastric cancer and metastatic colorectal cancer

1) Nukatsuka et al: Combination Chemotherapy Using TAS-102 and Irinotecan Hydrochloride, ANTICANCER RESEARCH 35: 1437-1446 (2015)

ASCELIA PHARMA

HIGH VALUE OPPORTUNITY IN GASTRIC CANCER AND EXPANSION

POTENTIAL FOR ORAL, DAILY DOSING OF IRINOTECAN[3]



A WELL-ESTABLISHED CHEMOTHERAPY
with recognized anti-tumor effect in solid tumors

- Current focus: **Gastric cancer**
  - Clinically demonstrated
  - Guidelines recognized
  - 3rd highest cancer deaths[1]
  - Orphan disease (US and EU)
  - $3-4bn market[2]
- **Approved indications** for IV irinotecan
- Indications where IV irinotecan are clinically demonstrated & guidelines recognized
- Indications where IV irinotecan are clinically demonstrated

1) International Agency for Research on Cancer (IARC, 2021)
2) GlobalData - Gastric and Gastroesophageal Junction Adenocarcinoma – Global Drug Forecast and Market Analysis to 2024
3) Globocan 2020, WHO, Cancer Research UK

ASCELIA PHARMA

ADVANCING
ORPHAN
ONCOLOGY

Ticker symbol: ACE
Nasdaq Stockholm
www.ascelia.com

Financials and Priorities

ASCELIA
PHARMA

FINANCIAL HIGHLIGHTS Q2 2023 – LIQUIDITY POSITION

- Liquid assets of 71 MSEK ($6.5 million) by 30 June 2023
- Ambition to complete the SPARKLE image re-evaluation with current cash
  - Activities not related to the re-evaluation are postponed and cost saving initiatives taken
  - We will communicate the timeline for the re-evaluation activity and the financial runway in mid September

Liquid assets including marketable securities
(SEK million)



FINANCIAL HIGHLIGHTS Q2 2023 – OPERATING RESULTS

- Increased operating loss in Q2 2023 compared to the loss in Q2 2022 due to a higher activity level in Ascelia Pharma in the current period vis-à-vis corresponding period last year. This was driven by costs related to Orviglance Phase 3 clinical study.

EBIT and cost items (SEK million)



Notes:
1) Other operating income and other operating costs added to SG&A

UNCHANGED CONFIDENCE IN ORVIGLANCE

ORVIGLANCE – a first-in-class orphan diagnostic drug targeting $800m market

✓	3 Mar 2023	Phase 3 LPLV
	Mid-Sept 2023	Focused Plan for Re-Evaluation

Oncoral – Phase 2 ready with attractive potential in gastric cancer and other solid tumors

ASCELIA PHARMA

ASCELIA PHARMA

ascelia.com

Follow us on LinkedIn